Wednesday, September 11, 2013

Though Icahn admitted Apple's stock could continue to decline in the near term, he thinks it's likely to climb higher over time. He went so far as to list it as one of his finer investments $AAPL

Though Icahn admitted Apple's stock could continue to decline in the near term, he thinks it's likely to climb higher over time. He went so far as to list it as one of his finer investments $AAPL

Icahn continued to advocate for a share buyback, calling it "ridiculous" that the company wouldn't take advantage of low rates to borrow the money and execute the transaction. Again, he called it a "no-brainer."
Though Apple's latest product announcement, the iPhone 5S and multicolored iPhone 5C, drew mixed reviews from consumers and investors alike, Icahn expressed little concern. After decades of asset management, Icahn said he's learned not to micromanage.
"Don't go in and tell somebody else how to run their business," Icahn said, "I look at it from the big picture. I just look at what they're doing. They're one of the best brands. They are building revenue."
Icahn went on to discuss his other positions.
Though he wouldn't guess where oil is headed, Icahn said he's bullish on Chesapeake because it has good assets and is being well run by CEO Doug Lawler following a recent reorganization effort.
Icahn slammed activist investor Bill Ackman's skepticism of Herbalife. Ackman has a $1 billion short bet against the company.
"I think Bill Ackman is completely wrong … it is not going to be closed down and the company has a great growth rate and I think it's still very undervalued," Icahn said. "And I think Ackman has no idea what he's talking about."
Earlier this year, Ackman and Icahn got into a very public flight over the company, but Icahn said "I don't even read what he writes anymore."
On Netflix, Icahn said the company "isn't what it was," but added he thinks CEO Reed Hastings is doing a "great job." He also disclosed he has yet to sell any shares of the video streaming service company.

No comments:

Post a Comment